Gupta R S
Cancer Treat Rep. 1985 May;69(5):515-21.
Stable mutants resistant to the anticancer drug vinblastine (VinR mutants) have been isolated after a single selection step from Chinese hamster ovary cells. Of the two types of VinR mutants which are obtained, one class exhibits specific cross-resistance to only some of the microtubule inhibitors. However, the second type of mutants, which is affected in membrane permeability, exhibits cross-resistance to a wide variety of unrelated compounds. Both classes of VinR mutants showed codominant expression in cell hybrids formed between resistant and sensitive cells. The cross-resistance patterns of the VinR mutants and a single-step mutant resistant to the anticancer drug taxol (TaxR mutant) toward various anticancer drugs have been determined. The mutants resistant to both of these drugs showed significantly increased resistance toward aclarubicin, dactinomycin, doxorubicin, bisantrene, bruceantin, chromomycin A3, demecolcine, colchicine, daunorubicin, ellipticine, emetine, ethidium bromide, maytansine, mithramycin, mitoxantrone, nitidine chloride, olivomycin, podophyllotoxin, puromycin, taxol, vinblastine, vincristine, vindesine, teniposide, and etoposide. Interestingly, either one or both of the above mutants exhibited somewhat enhanced sensitivity toward vidarabine, acivicin, bleomycin, cisplatin, cytarabine, alpha-difluoromethyl-ornithine, 5-FU, tegafur, and tiazofurin. For a number of other anticancer drugs which were examined (chlorambucil, mitolactol, IMPY, hexamethylmelamine, hydroxyurea, diglycoaldehyde, methotrexate, mitoguazone, mitomycin, nocodazole, and 6-thioguanine), the level of resistance of these mutants was found to be unaltered. The information regarding cross-resistance and collateral sensitivity patterns of VinR and TaxR mutants should prove to be very useful in the design of drug combinations which could prove more effective in cancer chemotherapy.
从中国仓鼠卵巢细胞经单一选择步骤后分离出了对抗癌药物长春碱具有抗性的稳定突变体(VinR 突变体)。在获得的两种类型的 VinR 突变体中,一类仅对某些微管抑制剂表现出特异性交叉抗性。然而,受膜通透性影响的第二类突变体对多种不相关化合物表现出交叉抗性。两类 VinR 突变体在抗性细胞与敏感细胞形成的细胞杂种中均表现出共显性表达。已确定 VinR 突变体和对抗癌药物紫杉醇具有抗性的单步突变体(TaxR 突变体)对各种抗癌药物的交叉抗性模式。对这两种药物均具有抗性的突变体对阿柔比星、放线菌素 D、多柔比星、比生群、鸦胆子素、色霉素 A3、去甲秋水仙碱、秋水仙碱、柔红霉素、椭圆玫瑰树碱、依米丁、溴化乙锭、美登素、光辉霉素、米托蒽醌、氯化两面针碱、橄榄霉素、鬼臼毒素、嘌呤霉素、紫杉醇、长春碱、长春新碱、长春地辛、替尼泊苷和依托泊苷的抗性显著增加。有趣的是,上述突变体中的一种或两种对阿糖腺苷、阿西维辛、博来霉素、顺铂、阿糖胞苷、α-二氟甲基鸟氨酸、5-氟尿嘧啶、替加氟和噻唑呋林表现出某种程度的敏感性增强。对于所检测的许多其他抗癌药物(苯丁酸氮芥、乳清酸氮芥、IMPY、六甲蜜胺、羟基脲、二甘醇醛、甲氨蝶呤、米托胍腙、丝裂霉素、诺考达唑和 6-硫鸟嘌呤),发现这些突变体的抗性水平未改变。关于 VinR 和 TaxR 突变体的交叉抗性和并列敏感性模式的信息在设计可能在癌症化疗中更有效的联合用药方面应会被证明非常有用。